New York Life Investment Management LLC Has $6.72 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

New York Life Investment Management LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW) by 0.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 90,833 shares of the medical research company’s stock after selling 332 shares during the quarter. New York Life Investment Management LLC’s holdings in Edwards Lifesciences were worth $6,724,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Nwam LLC lifted its position in shares of Edwards Lifesciences by 7.4% during the 4th quarter. Nwam LLC now owns 11,353 shares of the medical research company’s stock worth $840,000 after purchasing an additional 785 shares during the last quarter. Lake Street Advisors Group LLC lifted its position in shares of Edwards Lifesciences by 17.8% during the 4th quarter. Lake Street Advisors Group LLC now owns 3,661 shares of the medical research company’s stock worth $271,000 after purchasing an additional 552 shares during the last quarter. JFG Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth about $295,000. Los Angeles Capital Management LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth about $220,000. Finally, Prasad Wealth Partners LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at about $277,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.3 %

Shares of EW opened at $71.61 on Friday. The company has a market capitalization of $42.24 billion, a P/E ratio of 10.27, a PEG ratio of 4.82 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The business’s 50 day simple moving average is $72.64 and its 200-day simple moving average is $70.24.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the topic of several research reports. Piper Sandler boosted their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday, February 13th. Morgan Stanley boosted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday, February 12th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $82.00 to $90.00 in a research note on Monday, December 16th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Hold” and a consensus price target of $79.95.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,739 shares of company stock valued at $2,799,104. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.